[
  {
    "ts": null,
    "headline": "Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study",
    "summary": "MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.",
    "url": "https://finnhub.io/api/news?id=bb6687e954cd20b8677e280f31cd015f6e63b9d57035bcce6361882ab0675c4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732651200,
      "headline": "Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study",
      "id": 131654141,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.",
      "url": "https://finnhub.io/api/news?id=bb6687e954cd20b8677e280f31cd015f6e63b9d57035bcce6361882ab0675c4c"
    }
  },
  {
    "ts": null,
    "headline": "White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs",
    "summary": "More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.",
    "url": "https://finnhub.io/api/news?id=9134d813dd02d6ceedbb8a3a7ef7a15b3d3cd278b78cdf3304691d3491a986a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732617000,
      "headline": "White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs",
      "id": 131643473,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.",
      "url": "https://finnhub.io/api/news?id=9134d813dd02d6ceedbb8a3a7ef7a15b3d3cd278b78cdf3304691d3491a986a0"
    }
  },
  {
    "ts": null,
    "headline": "Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B",
    "summary": "RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.",
    "url": "https://finnhub.io/api/news?id=2c6b9f667839917946f63aa6c996f4d7fc0d7a7a1c8d364276dc89e46584f936",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732636740,
      "headline": "Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B",
      "id": 131652767,
      "image": "https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.",
      "url": "https://finnhub.io/api/news?id=2c6b9f667839917946f63aa6c996f4d7fc0d7a7a1c8d364276dc89e46584f936"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio Stock Up on FDA Approval of Cardiovascular Drug",
    "summary": "BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.",
    "url": "https://finnhub.io/api/news?id=ac8f6000fe7952acaa108972208cb8c1c1cc141da5bdef3aa5eed42212d63882",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732636260,
      "headline": "BridgeBio Stock Up on FDA Approval of Cardiovascular Drug",
      "id": 131653031,
      "image": "https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.",
      "url": "https://finnhub.io/api/news?id=ac8f6000fe7952acaa108972208cb8c1c1cc141da5bdef3aa5eed42212d63882"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=f5a47cefd9b3873c85ffdcccdcca3ddff0062ce6d2307f637cb0e86a005b644c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732629616,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 131646196,
      "image": "https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=f5a47cefd9b3873c85ffdcccdcca3ddff0062ce6d2307f637cb0e86a005b644c"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?",
    "summary": "Consider, for example, that a study by Hartford Funds and Ned Davis Research found that between 1973 and 2023, companies that grew or initiated dividend payments delivered annualized returns of 10.2%, while dividend non-payers delivered only 4.3% (and an equal-weight S&P 500 fund averaged 7.7%).  Healthy and growing dividend payers will tend to have stock prices that rise over time, while paying dividends that are also increased over time.  Given that stock profile, you might think it's smart to snap up the fattest dividend yields you can find -- perhaps focusing on the biggest dividend yields in the S&P 500.",
    "url": "https://finnhub.io/api/news?id=414fe22d634784076b186dfe96564ac07a05721308c8b970a65efcff0d5e707c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732627800,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?",
      "id": 131645741,
      "image": "https://g.foolcdn.com/editorial/images/798692/getty-serious-expression-at-table-thinking-considering.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Consider, for example, that a study by Hartford Funds and Ned Davis Research found that between 1973 and 2023, companies that grew or initiated dividend payments delivered annualized returns of 10.2%, while dividend non-payers delivered only 4.3% (and an equal-weight S&P 500 fund averaged 7.7%).  Healthy and growing dividend payers will tend to have stock prices that rise over time, while paying dividends that are also increased over time.  Given that stock profile, you might think it's smart to snap up the fattest dividend yields you can find -- perhaps focusing on the biggest dividend yields in the S&P 500.",
      "url": "https://finnhub.io/api/news?id=414fe22d634784076b186dfe96564ac07a05721308c8b970a65efcff0d5e707c"
    }
  },
  {
    "ts": null,
    "headline": "These Companies May Benefit the Most From Trump’s Proposed Corporate Tax Cuts",
    "summary": "These Companies May Benefit the Most From Trump’s Proposed Corporate Tax Cuts",
    "url": "https://finnhub.io/api/news?id=37a03915a35e0a059238b4037bfc7081ff88e9522e4e65b43bb59dc6c6eb9533",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732623540,
      "headline": "These Companies May Benefit the Most From Trump’s Proposed Corporate Tax Cuts",
      "id": 131776143,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "These Companies May Benefit the Most From Trump’s Proposed Corporate Tax Cuts",
      "url": "https://finnhub.io/api/news?id=37a03915a35e0a059238b4037bfc7081ff88e9522e4e65b43bb59dc6c6eb9533"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
    "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry.  Shares of Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have underperformed over the past couple of years, but these dividend payers kept raising their payouts.  With dividend payouts that have risen much faster than their stock prices, shares of these three drugmakers offer yields that are way above average.",
    "url": "https://finnhub.io/api/news?id=939e933cd1329d3df7dedeccc9f44747f7be0ba0849b56ee888042fcb80f2dc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732615380,
      "headline": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
      "id": 131637888,
      "image": "https://g.foolcdn.com/editorial/images/798603/couple-at-home-with-device-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry.  Shares of Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have underperformed over the past couple of years, but these dividend payers kept raising their payouts.  With dividend payouts that have risen much faster than their stock prices, shares of these three drugmakers offer yields that are way above average.",
      "url": "https://finnhub.io/api/news?id=939e933cd1329d3df7dedeccc9f44747f7be0ba0849b56ee888042fcb80f2dc6"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: Optimistic Outlook Despite The Recent Sell-Off",
    "summary": "Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read more on MRNA stock here.",
    "url": "https://finnhub.io/api/news?id=cc01c3557b934ab36c84c68c110b7793003bc3af588226a72baec5143c7da095",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732593087,
      "headline": "Moderna: Optimistic Outlook Despite The Recent Sell-Off",
      "id": 131629862,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read more on MRNA stock here.",
      "url": "https://finnhub.io/api/news?id=cc01c3557b934ab36c84c68c110b7793003bc3af588226a72baec5143c7da095"
    }
  }
]